<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04613193</url>
  </required_header>
  <id_info>
    <org_study_id>BP-AVALVE</org_study_id>
    <nct_id>NCT04613193</nct_id>
  </id_info>
  <brief_title>Blood Pressure Reduction in Patients With Asymptomatic Aortic VALVE Stenosis</brief_title>
  <acronym>BP-AVALVE</acronym>
  <official_title>Blood Pressure Reduction in Patients With Asymptomatic Aortic VALVE Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henrik Wiggers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danish Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aarhus University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the effect of strict blood pressure control versus&#xD;
      conventional care in patients with asymptomatic moderate to severe aortic valve stenosis.&#xD;
&#xD;
      The study is a randomized (1:1), open label, controlled intervention trial.&#xD;
&#xD;
      Hypothesis:&#xD;
&#xD;
        1. Strict BP control for 12 months reduces the progression of LV remodelling compared to&#xD;
           conventional treatment.&#xD;
&#xD;
        2. Strict BP control for 2 years reduces the increase in aortic valve calcification and LV&#xD;
           remodelling compared to conventional treatment.&#xD;
&#xD;
        3. Strict BP reduction for up to 10 years reduces the need for aortic valve replacement and&#xD;
           cardiovascular events compared to conventional care.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2031</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2031</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>1. BP-AVALVE I: 60 patients will be randomized (1:1) to either strict BP control (N=30) or conventional treatment (N=30). Treatment period will be 12 months.&#xD;
2. BP-AVALVE II: 200 patients will be randomized (1:1) to either strict BP control as in study 1 (N=100) or conventional care as in study 1 (N=100). Average treatment period will be 2 (1-3) years.&#xD;
3. BP-AVALVE III: Patients from BP-AVALVE-II continue in the randomized design until they develop symptoms of AS or have been followed for 10 (7-13) years. Patients will be reexamined at the end of the study period or in case they develop symptoms or LV failure and thus indication of valve replacement.&#xD;
Since the medicinal products used in this study is not the subject of the trial, the Danish Medicines Agency has classified this study as a clinical trial, in which medicinal products are used as a tool to induce a well-known physiological response. Therefor no further approval from the Danish Medicine Agency is required.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in LV mass</measure>
    <time_frame>Changes will be evaluated after an expected average of 12 months treatment</time_frame>
    <description>LV mass as measured by cardiac MR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in aortic valve CT calcium volume and aortic peak gradient</measure>
    <time_frame>Changes will be evaluated after an expected average of 2-3 years treatment</time_frame>
    <description>Cardiac CT and Echocardiography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical composite endpoint:</measure>
    <time_frame>Will be evaluated after an expected average of 7-13 years of treatment</time_frame>
    <description>Major cardiovascular events including death from cardiovascular causes, aortic valve replacement, non-fatal myocardial infarction, hospitalization for unstable angina pectoris, heart failure, coronary artery bypass surgery, percutaneous coronary intervention, and haemorrhagic and non-haemorrhagic stroke, new onset atrial fibrillation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>LV mass-cavity ratio.</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Cardiac MR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV myocardial fibrosis</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Cardiac MR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial perfusion during rest and stress</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Cardiac MR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aortic peak and mean gradients</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aortic valve area</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular global longitudinal strain</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Valvolu-arterial impedance</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NT-proBNP</measure>
    <time_frame>Baseline and follow-up</time_frame>
    <description>Blood test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minnesota living with heart failure questionnaire</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ambulatory 24-hour blood pressure measurement</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Ambulatory 24-hour blood pressure measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dimensions and aortic calcium score of the thoracic aorta.</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
    <description>cardiac CT</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Hypertension,Essential</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Strict BP intervention group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SBP &lt; 120 mmHg and a reduction in SBP of &gt;= 15 mmHg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional BP control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In patients &lt; 75 years: SBP = 135 mmHg In patients &gt;/= 75 years: SBP = 145 mmHg</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood presssure reduction</intervention_name>
    <description>Patients will be uptitrated in antihypertensive treatment until the treatment target is achieved.</description>
    <arm_group_label>Conventional BP control group</arm_group_label>
    <arm_group_label>Strict BP intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aortic valve peak velocity (Vmax) of 3.0-5.0 m/s and/or aortic valve area (AVA) ≤ 1.2&#xD;
             cm2&#xD;
&#xD;
          -  Blood pressure: SBP &gt;= 127 mmHg measured by BP-TRU&#xD;
&#xD;
          -  LVEF ≥ 50%&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Safe birth control management (intrauterine devices or hormonal contraceptives&#xD;
             (contraceptive pills, implants, transdermal patches, hormonal vaginal devices or&#xD;
             injections with prolonged release)) for women of childbearing potential.&#xD;
&#xD;
          -  Negative urine-HCG for women of childbearing potential&#xD;
&#xD;
          -  Ability to understand the written patient information and to give informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Symptoms due to AS&#xD;
&#xD;
          -  Symptomatic orthostatic hypotension and/or one minute standing SBP &lt; 110 mmHg (16).&#xD;
&#xD;
          -  Suspicion of secondary hypertension&#xD;
&#xD;
          -  Participation in other randomized drug study (device studies accepted)&#xD;
&#xD;
          -  Moderat to severe aortic valve regurgitation e.g. vena contracta &gt; 5 mm, assessed by&#xD;
             echocardiography)&#xD;
&#xD;
          -  Known or suspected ischemic heart disease (coronary angiography with &gt;70% stenosis in&#xD;
             a major epicardial vessel, symptoms or signs of myocardial ischemia, e.g. angina&#xD;
             pectoris, wall motion abnormalities). Patients who have previously undergone complete&#xD;
             revascularization of major coronary arteries due to angina pectoris are eligible for&#xD;
             inclusion.&#xD;
&#xD;
          -  Significant coronary obstructive lesions detected by baseline Cardiac CT that requires&#xD;
             a revascularisation procedure.&#xD;
&#xD;
          -  eGFR &lt; 30 ml/min or end-stage renal disease&#xD;
&#xD;
          -  Other disease, comorbidity or treatment making the subject unsuitable for study&#xD;
             participation as judged by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henrik Wiggers</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital, Department of Cardiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Henrik Wiggers, MD, PhD</last_name>
    <email>henrikwiggers@dadlnet.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jonas A Povlsen, MD</last_name>
    <phone>+452270282</phone>
    <email>jonapovl@rm.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dept. of Cardiology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henrik Wiggers</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Cardiology, Herning Hospital</name>
      <address>
        <city>Herning</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Morten Bøttcher</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of cardiology, Horsens Hospital</name>
      <address>
        <city>Horsens</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karen Kaae Dodt</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of cardiology, Randers Hospital</name>
      <address>
        <city>Randers</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Liv Gøtzsche</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Silkeborg Hospital</name>
      <address>
        <city>Silkeborg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lars Frost</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of cardiology, Viborg Hospital</name>
      <address>
        <city>Viborg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jens Refsgaard</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>July 9, 2020</study_first_submitted>
  <study_first_submitted_qc>October 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2020</study_first_posted>
  <last_update_submitted>October 27, 2020</last_update_submitted>
  <last_update_submitted_qc>October 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital</investigator_affiliation>
    <investigator_full_name>Henrik Wiggers</investigator_full_name>
    <investigator_title>Consultant, Associate professor, MD, PhD, DMSc</investigator_title>
  </responsible_party>
  <keyword>Aortic Valve Stenosis</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Heart failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Essential Hypertension</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

